Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms
Authors
Keywords
-
Journal
PHARMACOLOGICAL RESEARCH
Volume 188, Issue -, Pages 106667
Publisher
Elsevier BV
Online
2023-01-17
DOI
10.1016/j.phrs.2023.106667
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58
- (2022) Ahmed A. Kolkailah et al. DIABETES CARE
- The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation and increases ketosis
- (2022) Kristina Wallenius et al. JOURNAL OF LIPID RESEARCH
- Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: a meta-analysis
- (2022) Qiang Geng et al. JOURNAL OF HYPERTENSION
- Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes
- (2022) Domenico Tricò et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Pancreatic PCSK9 controls the organization of the β-cell secretory pathway via LDLR-cholesterol axis
- (2022) Algerta Marku et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
- (2022) Rosalba La Grotta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
- (2022) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
- (2022) Yue-Ming Gao et al. EBioMedicine
- Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
- (2022) Habib Yaribeygi et al. Journal of Clinical Medicine
- An integrative multiomic network model links lipid metabolism to glucose regulation in coronary artery disease
- (2021) Ariella T. Cohain et al. Nature Communications
- Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol
- (2021) Teruo Jojima et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors?
- (2021) Dimitrios Patoulias et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study
- (2021) Matthias Rau et al. ATHEROSCLEROSIS
- Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms
- (2021) Gianluigi Savarese et al. CARDIOVASCULAR RESEARCH
- Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials
- (2021) Søren S. Lund et al. DIABETES OBESITY & METABOLISM
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Major Renal Outcomes in Heart Failure
- (2021) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well‐controlled plasma LDL cholesterol
- (2020) Kristien E. C. Bouter et al. DIABETES OBESITY & METABOLISM
- Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
- (2020) Benedetta Maria Bonora et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus
- (2020) Steven B. Heymsfield et al. Obesity
- Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
- (2020) Francesco Cosentino et al. CIRCULATION
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials
- (2020) Adriana Sánchez-García et al. PHARMACOLOGICAL RESEARCH
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
- (2020) Darren K. McGuire et al. JAMA Cardiology
- Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials
- (2020) Gianluigi Savarese et al. ESC Heart Failure
- Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
- (2020) John J.V. McMurray et al. CIRCULATION
- Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
- (2019) Maria J. Pereira et al. DRUGS
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- Cholesterol metabolism, pancreatic β-cell function and diabetes
- (2019) Carla Perego et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploring novel pharmacotherapeutic applications and repurposing potential of sodium glucose CoTransporter 2 inhibitors
- (2018) Tushar Madaan et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor
- (2018) Lorenzo Da Dalt et al. EUROPEAN HEART JOURNAL
- Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition
- (2018) Debapriya Basu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
- (2017) David Fitchett et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels
- (2017) Harold E. Bays et al. Journal of Clinical Lipidology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
- (2016) Tim Heise et al. CLINICAL THERAPEUTICS
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
- (2016) François Briand et al. DIABETES
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- Statins and Diabetes
- (2016) Kevin C. Maki et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2016) Heidi Storgaard et al. PLoS One
- Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
- (2015) Nobuya Inagaki et al. ADVANCES IN THERAPY
- Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover stu
- (2015) R. Nishimura et al. DIABETES OBESITY & METABOLISM
- HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
- (2015) Daniel I Swerdlow et al. LANCET
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) Hans-Ulrich Häring et al. DIABETES CARE
- SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
- (2014) Masanori Yokono et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
- (2014) M Suzuki et al. Nutrition & Diabetes
- Glucose transport families SLC5 and SLC50
- (2013) Ernest M. Wright MOLECULAR ASPECTS OF MEDICINE
- Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats
- (2012) James J. Devenny et al. Obesity
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- HDL-C concentration is related to markers of absorption and of cholesterol synthesis: Study in subjects with low vs. high HDL-C
- (2010) V.S. Nunes et al. CLINICA CHIMICA ACTA
- Statins and risk of incident diabetes
- (2010) William G Simpson LANCET
- Balancing the benefits of statins versus a new risk—diabetes
- (2010) Christopher P Cannon LANCET
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
- (2010) Naveed Sattar et al. LANCET
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started